Bioaffinity Technologies, INC. (BIAFW) — SEC Filings

Q: What are the key financial highlights for Bioaffinity Technologies, INC.?

Key financial highlights for Bioaffinity Technologies, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bioaffinity Technologies, INC.?

Key executives at Bioaffinity Technologies, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bioaffinity Technologies, INC. stock?

Risk factors for Bioaffinity Technologies, INC. (BIAFW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bioaffinity Technologies, INC.?

Forward-looking statements and predictions from Bioaffinity Technologies, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bioaffinity Technologies, INC.. Recent 8-K filing on Dec 22, 2025. AI-decoded analysis of earnings, risk factors, and insider trades

View Bioaffinity Technologies, INC. on SEC EDGAR

Overview

Bioaffinity Technologies, INC. (BIAFW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: On December 22, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates that the company is involved in commercial physical and biological research, specifically within the SIC code 8731. The report was filed as of December 22, 2025, and pertains to 'Other Events'.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 10 bearish, 39 neutral. The dominant filing sentiment for Bioaffinity Technologies, INC. is neutral.

Filing Type Overview

Bioaffinity Technologies, INC. (BIAFW) has filed 34 8-K, 3 10-Q, 1 DEFA14A, 2 DEF 14A, 3 S-1/A, 5 S-1, 1 10-K/A, 1 10-K with the SEC between Nov 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

bioAffinity Technologies Files 8-K — 8-K · Dec 22, 2025 Risk: low
On December 22, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates that the company is involved in commercial physical and biologica
bioAffinity Technologies Files 8-K — 8-K · Dec 19, 2025 Risk: low
On December 19, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates that the company is involved in commercial physical and biologica
8-K Filing — 8-K · Dec 3, 2025
bioAffinity's Losses Double Amid Revenue Dip, Cash Influx from Offerings — 10-Q · Nov 14, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $11,772,288, up from $
DEFA14A Filing — DEFA14A · Nov 12, 2025
BioAffinity Seeks Shareholder Nod for Major Dilution, Equity Plan Boost — DEF 14A · Nov 7, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) is holding a Special Meeting of Stockholders on December 19, 2025, to address several critical financial and equity-relat
8-K Filing — 8-K · Nov 5, 2025
bioAffinity Technologies Files 8-K — 8-K · Oct 28, 2025 Risk: low
On October 28, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
bioAffinity Technologies Files 8-K — 8-K · Oct 20, 2025 Risk: low
On October 20, 2025, bioAffinity Technologies, Inc. filed a Form 8-K to report other events and financial statements. The company, incorporated in Delaware with
bioAffinity Technologies Files 8-K — 8-K · Oct 16, 2025 Risk: low
On October 16, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential u
bioAffinity Technologies Files 8-K — 8-K · Oct 15, 2025 Risk: low
bioAffinity Technologies, Inc. filed an 8-K on October 15, 2025, reporting on events that occurred on October 14, 2025. The filing includes information on finan
bioAffinity Technologies Files 8-K with Material Agreement — 8-K · Oct 9, 2025 Risk: medium
On October 8, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and fina
bioAffinity Technologies Files 8-K — 8-K · Oct 7, 2025 Risk: low
On October 7, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates no specific material events or financial updates were disclosed on
bioAffinity Technologies Files 8-K — 8-K · Sep 30, 2025 Risk: medium
On September 29, 2025, bioAffinity Technologies, Inc. entered into a material definitive agreement. The company also reported other events and filed financial s
bioAffinity Offers Shares Amid Nasdaq Delisting Threat, Reverse Split — S-1/A · Sep 25, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) is offering up to 729,927 shares of Common Stock and an equal number of Pre-Funded Warrants, alongside Placement Agent Wa
bioAffinity Launches Equity Offering Post-Split; No Minimum Raises Risk — S-1 · Sep 24, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) is offering up to 729,927 shares of Common Stock, alongside up to 1,094,891 Common Stock Purchase Warrants and up to 729,
bioAffinity Technologies Files 8-K on Corporate Changes — 8-K · Sep 17, 2025 Risk: low
On September 17, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing material modifications to security holder rights, amendments to its articles
bioAffinity Files S-1/A for Resale of 32.5M Shares by Selling Holders — S-1/A · Sep 15, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) filed an S-1/A on September 12, 2025, for the resale of up to 32,495,628 shares of common stock by various Selling Stockh
bioAffinity Technologies Files 8-K — 8-K · Sep 9, 2025 Risk: medium
On September 9, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits,"
bioAffinity Technologies to be Acquired — 8-K · Sep 5, 2025 Risk: medium
bioAffinity Technologies, Inc. announced on September 5, 2025, that it has entered into a definitive agreement to be acquired by an unaffiliated third party. Th
bioAffinity Technologies Files 8-K — 8-K · Sep 3, 2025 Risk: low
On September 3, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits,"
bioAffinity Technologies Files 8-K — 8-K · Sep 2, 2025 Risk: medium
On September 2, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also
bioAffinity Files S-1 for Resale of 12.6M Shares by Selling Stockholders — S-1 · Aug 29, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) filed an S-1 on August 29, 2025, for the resale of up to 12,611,253 shares of common stock by Selling Stockholders. This
bioAffinity Technologies Announces Board and Executive Changes — 8-K · Aug 18, 2025 Risk: medium
bioAffinity Technologies, Inc. announced on August 12, 2025, a change in its board of directors and executive compensation arrangements. The filing details the
bioAffinity's Losses Widen Amid Revenue Drop, Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
bioAffinity Technologies, Inc. (BIAFW) reported a significant net loss of $6.72 million for the six months ended June 30, 2025, a substantial increase from the
bioAffinity Technologies Faces Delisting Concerns — 8-K · Aug 13, 2025 Risk: high
bioAffinity Technologies, Inc. filed an 8-K on August 13, 2025, reporting events as of August 7, 2025. The filing indicates a notice of delisting or failure to
bioAffinity Technologies Files 8-K — 8-K · Jul 31, 2025 Risk: low
bioAffinity Technologies, Inc. filed an 8-K on July 31, 2025, reporting events as of July 29, 2025. The filing includes information on "Other Events" and "Finan
bioAffinity Technologies Files 8-K on Security Holder Vote Matters — 8-K · Jul 25, 2025 Risk: low
On July 25, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated
bioAffinity Technologies Files 8-K — 8-K · Jul 23, 2025 Risk: low
On July 23, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. No specific
bioAffinity Technologies Files 8-K — 8-K · Jul 22, 2025 Risk: low
On July 22, 2025, bioAffinity Technologies, Inc. filed a Form 8-K to report other events and financial statements. The company, incorporated in Delaware with it
bioAffinity Technologies Files 8-K Report — 8-K · Jul 15, 2025 Risk: low
On July 15, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 3300 Nacogdo
bioAffinity Pushes Early Lung Cancer Dx; Annual Meeting Set — DEF 14A · Jun 2, 2025 Risk: medium
bioAffinity Technologies, Inc. filed a Definitive Proxy Statement (DEF 14A) on June 2, 2025, for its Annual Meeting of Stockholders scheduled for July 25, 2025,
bioAffinity Technologies Faces Delisting Notice — 8-K · May 30, 2025 Risk: high
bioAffinity Technologies, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of May 27, 2025. T
bioAffinity Technologies Enters Material Definitive Agreement — 8-K · May 27, 2025 Risk: medium
On May 22, 2025, bioAffinity Technologies, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive
bioAffinity Technologies Files 8-K on Shareholder Nominations — 8-K · May 19, 2025 Risk: medium
On May 19, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns shareholder nominations pursuant to Exchange Act Rule 14a-11,
bioAffinity Technologies Q1 2025 10-Q Filing — 10-Q · May 15, 2025 Risk: medium
bioAffinity Technologies, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on commercial physical and biological resea
bioAffinity Technologies Files 8-K — 8-K · May 8, 2025 Risk: medium
On May 5, 2025, bioAffinity Technologies, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statemen
bioAffinity Technologies Files S-1/A Amendment — S-1/A · May 5, 2025 Risk: medium
bioAffinity Technologies, Inc. filed an S-1/A amendment on May 5, 2025, related to its 1933 Act registration. The company, based in San Antonio, TX, is involved
bioAffinity Technologies Files S-1 for Public Offering — S-1 · May 2, 2025 Risk: medium
bioAffinity Technologies, Inc. filed an S-1 form on May 2, 2025, indicating a public offering. The company, based in San Antonio, TX, is involved in commercial
bioAffinity Technologies Files 10-K Amendment — 10-K/A · Apr 29, 2025 Risk: medium
bioAffinity Technologies, Inc. filed an amendment (Amendment No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company,
bioAffinity Technologies Announces Board and CFO Changes — 8-K · Apr 14, 2025 Risk: medium
On April 12, 2025, bioAffinity Technologies, Inc. announced changes in its board of directors and executive compensation. The company elected two new directors,
bioAffinity Technologies Files S-1 for Public Offering — S-1 · Apr 11, 2025 Risk: medium
bioAffinity Technologies, Inc. filed an S-1 form on April 11, 2025, indicating a public offering. The company, based in San Antonio, TX, is involved in commerci
bioAffinity Technologies Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
bioAffinity Technologies, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in San Antonio,
bioAffinity Technologies Closes $1.5M Private Placement — 8-K · Mar 7, 2025 Risk: medium
On March 6, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing several events. The company announced the closing of a private placement offering
bioAffinity Technologies Files 8-K with Key Agreements — 8-K · Feb 27, 2025 Risk: medium
On February 25, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing several events. These include entering into a material definitive agreement,
bioAffinity Technologies Faces Delisting Notice — 8-K · Feb 7, 2025 Risk: high
bioAffinity Technologies, Inc. filed an 8-K on February 7, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is
bioAffinity Tech Appoints New Director, CEO Gets New Contract — 8-K · Jan 14, 2025 Risk: medium
On January 10, 2025, bioAffinity Technologies, Inc. announced changes in its board of directors and executive compensation. Specifically, the company elected Dr
bioAffinity Technologies Files 8-K on Shareholder Vote — 8-K · Dec 23, 2024 Risk: medium
bioAffinity Technologies, Inc. filed an 8-K on December 23, 2024, reporting on a matter submitted to a vote of security holders on December 20, 2024. The filing
bioAffinity Technologies Files 8-K — 8-K · Dec 20, 2024 Risk: low
On December 19, 2024, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includ
bioAffinity Technologies Files S-1 — S-1 · Nov 27, 2024 Risk: medium
bioAffinity Technologies, Inc. filed an S-1 form on November 27, 2024, detailing its financial status. For the nine months ended September 30, 2024, the company

Risk Profile

Risk Assessment: Of BIAFW's 47 recent filings, 10 were flagged as high-risk, 22 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioaffinity Technologies, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: $4.57M
Net Income: -$11.77M
Cash Position: $7.67M

Key Executives

Maria Zannes
Richard A. Friedman, Esq.
Sean F. Reid, Esq.
Ross D. Carmel, Esq.
Jeffrey Wofford, Esq.
Richard A. Friedman
Sean F. Reid
Dr. Steven A. Smith
Mr. David L. Smith
Mr. Michael L. Smith
Dr. Joseph M. Smith
Dr. Richard A. U. Smith

Industry Context

bioAffinity Technologies operates in the diagnostics and therapeutics sector, focusing on early cancer detection. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing to fund clinical trials and commercialization efforts.

Top Tags

filing (12) · financials (9) · Biotechnology (8) · 8-K (7) · 8-k (7) · Diagnostics (6) · material-agreement (6) · research (5) · Warrants (4) · disclosure (4)

Key Numbers

SEC File Number: 001-41463 — Identifier for bioAffinity Technologies, Inc.'s SEC filings.
EIN: 46-5211056 — Employer Identification Number for bioAffinity Technologies, Inc.
Net Loss (9 months ended Sep 30, 2025): $11.77M — Increased from $6.07M in 2024, indicating worsening financial performance.
Net Revenue (9 months ended Sep 30, 2025): $4.57M — Decreased from $7.15M in 2024, showing a decline in sales.
Cash and Cash Equivalents (Sep 30, 2025): $7.67M — Increased significantly from $1.11M at Dec 31, 2024, due to financing activities.
Net Cash Provided by Financing Activities (9 months ended Sep 30, 2025): $13.39M — Primary source of cash influx, including stock offerings and warrant exercises.
Fair Value Adjustment on Warrants (9 months ended Sep 30, 2025): $3.81M — Significant non-cash expense contributing to the increased net loss.
Common Stock Shares Outstanding (Nov 11, 2025): 4,498,709 — Reflects increased share count due to recent offerings and exercises.
Proceeds from Issuance of Common Stock (9 months ended Sep 30, 2025): $9.27M — Major component of financing activities, indicating significant dilution.
Proceeds from Exercise of Warrants (9 months ended Sep 30, 2025): $4.81M — Another substantial source of financing, contributing to cash increase.
Common Stock issuable: 271,500 shares — Upon exercise of August 2025 Warrants, potentially exceeding 20% of outstanding Common Stock
Maximum Common Stock issuable: 365,620 shares — Upon exercise of August 2025 Warrants after anti-dilution adjustment
Floor price: $4.50 per share — For reduced exercise price of August 2025 Warrants
New Common Stock reserved: 750,000 shares — For the 2024 Equity Incentive Plan, up from 66,666 shares
Current Common Stock reserved: 66,666 shares — For the 2024 Equity Incentive Plan, prior to proposed amendment

Related Companies

BIAF

Frequently Asked Questions

What are the latest SEC filings for Bioaffinity Technologies, INC. (BIAFW)?

Bioaffinity Technologies, INC. has 50 recent SEC filings from Nov 2024 to Dec 2025, including 34 8-K, 5 S-1, 3 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BIAFW filings?

Across 50 filings, the sentiment breakdown is: 1 bullish, 10 bearish, 39 neutral. The dominant sentiment is neutral.

Where can I find Bioaffinity Technologies, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bioaffinity Technologies, INC. (BIAFW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bioaffinity Technologies, INC.?

Key financial highlights from Bioaffinity Technologies, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BIAFW?

The investment thesis for BIAFW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bioaffinity Technologies, INC.?

Key executives identified across Bioaffinity Technologies, INC.'s filings include Maria Zannes, Richard A. Friedman, Esq., Sean F. Reid, Esq., Ross D. Carmel, Esq., Jeffrey Wofford, Esq. and 7 others.

What are the main risk factors for Bioaffinity Technologies, INC. stock?

Of BIAFW's 47 assessed filings, 10 were flagged high-risk, 22 medium-risk, and 15 low-risk.

What are recent predictions and forward guidance from Bioaffinity Technologies, INC.?

Forward guidance and predictions for Bioaffinity Technologies, INC. are extracted from SEC filings as they are enriched.